Medivir AB Shareholders Approve Directed Share Placement to Hallberg Management at Extraordinary General Meeting

Shareholder Approval Finalizes Hallberg Management Directed Placement

At the extraordinary general meeting in Huddinge on 20 July 2026, Medivir AB shareholders officially approved the Board’s resolution to issue up to 6,097,560 new ordinary shares to Hallberg Management AB. This shareholder endorsement completes a two-step process initiated by the Board on 17 June 2026. The directed placement constitutes Tranche 2 of a previously announced capital raise, following initial allocations to Swedish and international institutional investors in Tranche 1.

Securing shareholder approval provides Medivir with certainty regarding the capital injection from Hallberg Management. Opting for explicit shareholder consent at an extraordinary general meeting, rather than relying solely on Board authority, underscores the company’s commitment to transparency and governance. The targeted nature of the placement towards a specific institutional investor indicates strategic intentions for capital structure and partnership alignment rather than a broad public offering.

Medivir’s Focus on Oncology and Rare Bone Disease Therapeutics

Medivir is a Swedish pharmaceutical developer concentrating on innovative treatments for diseases with significant unmet medical needs. The company’s R&D efforts target indications lacking effective therapies, positioning it within a high-risk, high-reward segment of pharma development. This strategic focus on underserved patient populations guides Medivir’s operational and capital allocation strategies.

The company’s two lead drug candidates are key value drivers. Fostrox is designed as a precision chemotherapy targeting liver cancer cells selectively to minimize damage to healthy tissue, aiming to reduce side effects compared to conventional chemotherapy. MIV-711 targets two rare genetic bone disorders: Osteogenesis Imperfecta (brittle bone disease) and Legg-Calvé-Perthes disease, affecting children’s hip joints. Both candidates are described as having blockbuster potential, reflecting Medivir’s expectations of their commercial impact pending regulatory approval and market uptake.

Hybrid Development Model and Strategic Partnerships

Medivir employs a hybrid development approach combining in-house research with external collaborations to advance its drug pipeline. This model enables leveraging internal expertise while maintaining financial flexibility through partnerships. Such collaborations are integral to Medivir’s strategy, especially as a small-cap Swedish pharmaceutical company, providing capital efficiency and third-party validation.

The capital raised via the Hallberg Management placement supports this collaborative framework, ensuring resources to progress fostrox and MIV-711 through clinical stages while preserving options for strategic partnerships. Listed on Nasdaq Stockholm’s Small Cap segment, Medivir’s current market capitalization reflects its development stage, but the blockbuster potential of its lead assets suggests significant upside if milestones are met.

Two-Tranche Capital Raise and Institutional Investor Engagement

Medivir structured its capital raise in two directed placement tranches targeting Swedish and international institutional investors, with Tranche 2 allocated to Hallberg Management AB. This phased approach reflects strategic sequencing based on investor demand and capital partner prioritization. The Board’s resolution on 17 June 2026 initiated the process, requiring shareholder approval at the extraordinary general meeting before finalization.

Institutional investor participation, including Hallberg Management’s substantial allocation of up to 6,097,560 shares, demonstrates market interest in Medivir’s therapeutic pipeline despite inherent pharmaceutical development risks. The shareholder approval removes regulatory and procedural barriers, allowing settlement and registration of new shares with the Swedish Financial Supervisory Authority and Nasdaq Stockholm.

Medivir’s Nasdaq Stockholm Listing and Governance Practices

Medivir AB is listed on Nasdaq Stockholm under ticker MVIR within the Small Cap segment, granting access to capital markets, shareholder liquidity, and regulatory oversight by Swedish and European authorities. The small-cap classification aligns with its market capitalization and operational scale, offering accessibility to both retail and institutional investors.

The 20 July 2026 extraordinary general meeting exemplifies formal shareholder engagement consistent with Swedish corporate governance standards. Meeting minutes will be published on Medivir’s website within two weeks, ensuring transparency regarding shareholder discussions, voting outcomes, and Board responses. This openness fosters market confidence in governance and informs current and prospective shareholders.

Fostrox: Precision Chemotherapy Targeting Liver Cancer

Fostrox is Medivir’s lead oncology candidate, developed as a precision chemotherapy that selectively targets liver cancer cells while minimizing cytotoxic exposure to healthy tissue. This approach addresses the toxicity challenges of conventional chemotherapy, potentially improving tolerability and patient quality of life.

Liver cancer, including hepatocellular carcinoma, remains a major global health challenge with limited treatment options. Medivir’s investment in fostrox, supported by institutional capital, highlights confidence in its scientific rationale and commercial prospects, though clinical and regulatory risks remain inherent.

MIV-711: Addressing Rare Genetic Bone Disorders

MIV-711 targets two rare genetic bone diseases: Osteogenesis Imperfecta, characterized by fragile bones due to collagen defects, and Legg-Calvé-Perthes disease, which impairs hip joint development in children. Both conditions have limited treatment options, aligning with Medivir’s focus on high unmet medical needs.

Developing MIV-711 addresses significant clinical gaps and offers potential commercial benefits through orphan drug designations and premium pricing. The company’s classification of MIV-711 as having blockbuster potential reflects projected market size and adoption if approved. Continued development depends on sustained capital investment, supported by the recent capital raise.

Blockbuster Potential and Shareholder Value Outlook

Medivir explicitly describes fostrox and MIV-711 as possessing blockbuster potential, indicating expected annual sales exceeding one billion dollars if successful. This outlook forms a core value proposition for shareholders, contingent upon clinical success, regulatory approval, and market acceptance.

While optimistic, such projections carry risks given the high failure rates in pharmaceutical development. The Hallberg Management capital raise provides necessary funding to advance both programmes, with clinical progress serving as key milestones. Investors should monitor trial results, regulatory updates, and partnership developments as indicators of progress toward these blockbuster goals.

Governance, Transparency, and Investor Relations

Medivir’s decision to seek shareholder approval for the Hallberg Management placement reflects strong governance and transparency standards aligned with Nasdaq Stockholm requirements. The company will publish comprehensive minutes from the extraordinary general meeting on its website within two weeks, ensuring broad access to official shareholder decision records.

Jens Lindberg, CEO of Medivir, serves as the primary contact for further information. This accessibility supports investor relations by facilitating communication between management and capital providers. Stakeholders are encouraged to follow developments in fostrox and MIV-711 clinical programmes, regulatory filings, partnership announcements, and capital allocation updates via official Nasdaq Stockholm news releases and Medivir’s website at www.medivir.com.